Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535903 | 0.82 | MAPT (0.42) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8519232 | 0.75 | PTGDR2 (0.38) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8519230 | 0.75 | PTGDR2 (0.38) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8619689 | 0.74 | PTGDR2 (0.45) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8619691 | 0.74 | PTGDR2 (0.45) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL54335 | 0.74 | ALDH1A1 (0.46) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5360660 | 0.74 | ALDH1A1 (0.46) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8622364 | 0.74 | PTGDR2 (0.44) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8622366 | 0.74 | PTGDR2 (0.44) | MAPTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL8519540 | 0.72 | ALDH1A1 (0.42) | MAPTNPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362212-B1 | POTENT FUNGICIDAL ACTIVITY | SHIONOGI & COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020032227-A1 | Oxime derivative and bactericide containing the same as active ingredient | TAKASE AKIRA (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6268312-B1 | FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6048885-A | FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0754684-A1 | OXIME DERIVATIVE AND BACTERICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIONOGI & CO., LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032227-A1 | Oxime derivative and bactericide containing the same as active ingredient | MSMO1, O60361, CBR1 | MAPT 4733/4885NPC1 3604/4885RAB9A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.